|Day Low/High||147.33 / 149.92|
|52 Wk Low/High||114.53 / 196.08|
McCaskill requested that four more drug companies and three drug distributors turn over documents.
McKesson faced some opposition at its shareholder meeting from an unconventional activist investor—a labor union.
McKesson Corporation (NYSE:MCK) today reported that revenues for the first quarter ended June 30, 2017 were $51.
The Board of Directors of McKesson Corporation (NYSE:MCK) today declared a regular dividend of thirty-four cents per share on Common Stock, a twenty-one percent increase from twenty-eight cents per share in the prior...
McKesson Corporation (NYSE:MCK) today announced preliminary voting results from its Annual Meeting of Stockholders, held earlier today in Irving, Texas.
ISS and Glass, Lewis echo the union's call for management to address the drug distributor's role in the opioid crisis.
Here's what you need to know now.
Here's a look at what Jim Cramer had to say about companies of interest to Mad Money viewers.
Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.
McKesson Corporation (NYSE:MCK) will release financial results for its first fiscal quarter ended June 30, 2017 on Thursday, July 27, 2017, prior to the opening of trading on the New York Stock Exchange.
The trial's success props open doors for exploring new uses for Opdivo's treatment in immunotherapy.
Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.
McKesson Corporation (NYSE:MCK) today reaffirmed its earnings guidance for the fiscal year ending March 31, 2018 and the underlying key assumptions provided in its press release on May 18, 2017.
McKesson Corporation (NYSE:MCK) will host an Investor Day in Boston on Wednesday, June 28, 2017, including presentations by John Hammergren, chairman, president and chief executive officer; James Beer, executive vice...
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Here is what you need to know.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 874,390 share decrease in total short interest for McKesson Corp , to 3,950,969, a decrease of 18.12% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Watch those valuations.
Walmart retains the top spot for the fifth straight year with 2016 revenues totaling $485.9 billion.
Here are Tuesday's top research calls, including downgrades for Ambarella and BlackBerry, and upgrades for PVH Corp. and Zynga.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MCK, MRVL, NSH, TEF Downgrades: ANW, BOSC, FET, GPX, MIXT, UAN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
McKesson Corporation (NYSE:MCK) today announced that James Beer, executive vice president and chief financial officer, will present at the Goldman Sachs 38 th Annual Global Healthcare Conference in Rancho Palos Verdes at...
The Board of Directors of McKesson Corporation (NYSE:MCK) today declared a regular dividend of twenty-eight cents per share on Common Stock.
The firm's analyst believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted.